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SUMMARY
1. Hypertensive mice expressing the human renin (REN) and
angiotensinogen (AGT) genes are used as a model for human
hypertension.
2. The aim of the present study was to investigate the cellular
expression and distribution of inducible nitric oxide synthase
(iNOS) using immunohistochemistry in lung, heart and kidney
tissues from a model of human hypertension using male and
female double-transgenic (h-Ang 204/1h-Ren6) mice and
wild-type C57/BI6J mice as controls.
3. In the kidney, the pattern of iNOS expression in various
renal microanatomical regions during hypertension was similar
to that of age-matched controls, except in the medullary ascending
limb (MAL). In hypertension, iNOS expression was downregulated
in the MAL. No significant differences in iNOS expression were
seen between control or hypertensive mice in various cardiac
microanatomical locations. In the lungs of hypertensive mice,
iNOS expression was upregulated in bronchial airway epithelium
and bronchial and vascular smooth muscle cells, but down-
regulated in alveolar macrophages, alveolar septa and pulmonary
vascular endothelial cells. Expression of iNOS was similar
between male and female mice in the kidney, heart and lungs.
4. In conclusion, iNOS regulation in hypertension is complex
and depends on the cell type in which it is expressed and the
localization of the cell type in the cardiorenal and pulmonary
systems.
Key words: angiotensin, hypertension, inducible nitric oxide
synthase, renin.
INTRODUCTION
The renin (REN)–angiotensin–aldosterone system (RAAS) plays an
important role in the control of cardiovascular and renal homeostasis
by regulating blood pressure (BP) and fluid volume.1,2 Angiotensin
(Ang) II is produced via an enzymatic cascade that begins with
angiotensinogen (AGT) cleaving REN to form AngI, which is then
cleaved by angiotensin-converting enzyme (ACE) to form AngII.3
The genes for REN and AGT have been linked to, or associated with,
hypertension in animal models and humans.2 Transgenic rodent
models have been developed that overexpress both human REN and
AGT, which leads to hypertension via chronic overproduction of
AngII. Specific examples include the murine double-transgenic line
(h-Ang 204/1h-Ren 9), which produces a mean arterial BP 40 mmHg
higher than wild-type mice (C57Bl/6J) that lack the human genes.2
In addition, transgenic rats harbouring the mouse REN-2 gene devel-
oped hypertension, cardiac hypertrophy and renal damage.4 Tsukuba
hypertensive mice (THM), which express human REN and AGT
genes, have also been shown to develop hypertension.5 There is
increasing evidence suggesting that a RAAS may reside within several
organs, including the kidney, lung, heart and in vascular smooth
muscle cells (VSMC), where it is believed to act in a functionally
independent paracrine/autocrine fashion.6 This hypothesis is further
supported by the fact that all components of the RAAS in the heart,
kidney and lung contain the ACE component.3,6 In addition, high
concentrations of AngII have been demonstrated in the plasma, heart
and kidney of THM.7,8
Inducible nitric oxide synthase (iNOS) is a calcium-independent
inducible isoform of nitric oxide synthase (NOS) that can be induced
by various cytokines.9 In the kidney, nitric oxide (NO) and iNOS
may have various roles, including in hypertension.9,10 Inhibition of
NO synthesis has also been demonstrated to decrease plasma REN
activity11 and long-term inhibition of NO leads to AngII-dependent
hypertension.12 Therefore, NO appears to have a role in RAAS-
mediated hypertension.
There are currently no published reports on the cellular expression
and microanatomical distribution of iNOS in hypertensive double-
transgenic mice expressing human REN and AGT genes. Therefore,
using immunohistochemistry, we investigated the microanatomical
location and cellular expression of iNOS in kidney, lung and heart
tissues obtained from REN–AGT-transgenic mice and age-matched
controls. The present study is the first to report on the pulmonary
and cardiorenal microanatomical cellular expression and distribution
of iNOS and possible mechanistic pathophysiological insights in this
model of human hypertension.
METHODS
Animals
The present study used 15–20-week-old male (n = 15) and female (n = 15)
double-transgenic mice (h-Ang 204/1h-Ren 9). The mice were derived from
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a founder colony of five male mice expressing human AGT (h-Ang 204/1)
and six females expressing human REN (h-Ren 6), obtained from Dr Curt
Sigmund at the University of Iowa School of Medicine (Iowa City, IA, USA).
At Charles River Laboratories (Wilmington, MA, USA), female mice that
expressed human REN were bred with AGT-expressing male mice to produce
the double-transgenic line. The transgenic line was developed on a C57/BI6J
background. Details of the generation and phenotype of the double transgenic
mouse are described elsewhere.13,14 Age-matched male (n = 10) and female
(n = 10) C57/BI6J mice were used as controls. All procedures were in
compliance with the Pfizer Ann Arbor Laboratories Animal Care and Use
Committee.
Haemodynamic parameters
The haemodynamic changes in this model have been well characterized pre-
viously.15 Briefly, transgenic mice were prepared with in-dwelling aortic
catheters and radiotransmitters (Data Sciences International, St Paul, MN,
USA). The catheters were placed in the left carotid artery and advanced to the
aortic arch. The radiotransmitters allowed continuous measurement of the aortic
BP waveform, from which mean arterial pressure (MAP) and heart rate (HR) were
derived using Ponemah software (Gould Instruments, Valley View, OH, USA).
Study tissue samples
Lung, kidney and heart tissues were obtained from mice at the time of
necropsy. Tissues were fixed in 10% neutral buffered formalin for 24 h and
embedded in paraffin wax. Sections (3 m) were then cut and stained immu-
nohistochemically with antibodies against iNOS.
Immunohistochemistry for iNOS
To analyse the expression of iNOS, 3 m sections were cut from formalin-
fixed, paraffin-embedded blocks, mounted on positively charged glass slides,
dried and then loaded on the automated immunostainer at room temperature
using a Ventana Immunostainer System (Ventana Medical Systems, Tucson,
AZ, USA). Slides were deparaffinized and then rehydrated. Sections were
incubated for 30 min with serum-free DakoCytomation protein blocker
(Dako Corporation, Dako, CA, USA) and then rinsed and incubated for 4 min
with avidin–biotin blocking solution (Ventana Medical Systems). Antigen
retrieval was completed with a Ventana specialty solution (pH = 8; Ventana
Medical Systems).
Automation included exposure to 100 L primary anti-iNOS antibody
(Cayman Chemical, Ann Arbor, MI, USA) diluted 1 : 100 with reagent diluent
(Ventana Medical Systems) at room temperature for 60 min, followed by the
addition of 100 L of the appropriate anti-rabbit biotinylated IgG linking
solution (1 : 200 dilution; Vector Laboratories) to each section for 60 min at
room temperature. Sections were rinsed with buffer and allowed to react with
100 L diaminobenzidine (DAB) substrate solution (DAB Detection Kit;
Ventana Medical Systems) for 8 min, followed by counterstaining with
haematoxylin and then bluing reagent for 4 min each, removed from the
autostainer, washed in warm water, dehydrated through graded alcohol,
cleared in xylene and cover slipped. Control reactions included: (i) sections
incubated with the omission of primary antibody, but otherwise processed
as described above; and (ii) sections incubated with normal rabbit serum
instead of the primary antibody and the processed as described above.
Expression of iNOS was evaluated semiquantitatively. Staining (percentage
of immunostained cells) was scored as follows: –, no staining; +, minimal
staining; ++, mild staining (< 30% of the cell population stained); +++,
moderate staining (< 60% of the cell population stained); and ++++, strong
staining (> 60% of cells stained).
RESULTS
Pulmonary and cardiorenal cellular expression and distribution of
iNOS are summarized in Tables 1 and 2. Staining intensity ranged
from negative (–) to strong (++++).
In the kidney of hypertensive mice, moderate (+++) diffuse cyto-
plasmic iNOS expression occurred in the distal convoluted tubules,
cortical collecting ducts and medullary collecting ducts, whereas
mild (++) iNOS expression was observed in the macula densa and
proximal convoluted tubules (Fig. 1; Table 1). This pattern of iNOS
expression was similar to that of age-matched control mice. Minimal
(+) diffuse iNOS cytoplasmic staining was present in cortical and
medullary interstitial cells (IC) and the medullary ascending limb
(MAL) in hypertensive mice. Conversely, in control mice, mild (++)
diffuse iNOS cytoplasmic expression was observed in cortical and
medullary IC and moderate (+++) staining was seen in the MAL.
In hypertensive mice, iNOS expression was lacking in the glomerular
visceral epithelium, capsular parietal epithelium, glomerular podocytes,
vascular endothelial cells (EC) and VSMC. This expression pattern
was similar to that of controls, with the exception of minimal iNOS
expression in vascular EC, glomerular visceral epithelium and capsular
parietal epithelium.
In hypertensive mice, pulmonary expression of iNOS included
strong diffuse staining in bronchial smooth muscle cells (SMC) and
Table 1 Renal immunohistochemical expression of inducible nitric oxide
synthase
Cellular location Control Hypertension
Macula densa ++ ++
Proximal convoluted tubules +++ ++
Distal convoluted tubules +++ +++
VSMC – –
Vascular EC + –
Cortical IC ++ +
Medullary IC ++ +
Glomeruli (podocytes) – –
Glomerular (visceral) epithelium + –
Capsular (parietal) epithelium + –
Cortical collecting ducts +++ +++
Medullary collecting ducts +++ +++
MAL +++ +
–, no staining; +, minimal staining; ++, mild staining; +++, moderate
staining; VSMC, vascular smooth muscle cells; EC, endothelial cells;
IC, interstitial cells; MAL, medullary ascending limb.
Table 2 Pulmonary and cardiac immunohistochemical expression of
inducible nitric oxide synthase
Cellular location Control Hypertension
Alveolar macrophages +++ +
Alveolar septa +++ +
Bronchial epithelium – ++
Bronchial SMC + ++++
Bronchiolar epithelium – –
Pulmonary vascular EC +++ –
Pulmonary VSMC ++ ++++
Cardiac myocytes +++ ++++
Cardiac VSMC + –
Cardiac vascular EC – –
–, no staining; +, minimal staining; ++, mild staining; +++, moderate
staining; ++++, strong staining; VSMC, vascular smooth muscle cells;
EC, endothelial cells; SMC, smooth muscle cells.
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VSMC (Fig. 2; Table 2), whereas minimal (bronchial SMC) and
mild (VSMC) expression was present in lungs from control mice.
Mild staining was present in the bronchial epithelium and minimal
staining was present in the alveolar macrophages and septa. In control
mice, moderate staining was observed in alveolar macrophages and
septa, and no expression was present in the bronchial epithelium.
There was no iNOS expression in the bronchiolar epithelium of lungs
from either normal or hypertensive mice. In addition, there was no
iNOS expression in the vascular EC in lungs from hypertensive
mice, whereas in control mice moderate iNOS expression was found
in the vascular EC.
Cardiac myocytes from both hypertensive and control mice had
moderate to strong iNOS expression, whereas cardiac vascular SMC
and EC from hypertensive mice were negative for iNOS (Fig. 3;
Table 2). In control mice, minimal iNOS expression was present in
cardiac VSMC and there was no iNOS expression in cardiac vascular
EC. All these expression patterns for iNOS were similar between
male and female mice.
DISCUSSION
Within the kidney, NO contributes to the regulation of glomerular
haemodynamics and blood pressure control.10,16,17 In fact, the gene
locus coding for iNOS has been shown to cosegregate with blood
pressure in the Dahl salt-sensitive rat18 and blood pressure is
increased in iNOS-deficient mice compared with that in wild-type
controls.19 In addition, continuous infusion for 6 days of amino-
guanidine, a selective iNOS inhibitor, increased MAP in rats.10 Although
iNOS is only induced by pro-inflammatory factors in most tissues,
in situ hybridization and reverse transcription–polymerase chain reac-
tion experiments have shown that iNOS is expressed constitutively
in the renal medulla and proximal tubules and to a high degree in
various regions of the normal rodent kidney, where iNOS partici-
pates in the regulation of renal function and arterial pressure.20,21 In
the present study, the overall pattern of iNOS expression in the kidney
was similar to that of age-matched control mice, with the exception
of downregulation of iNOS expression in the MAL in hypertensive
mice. The high degree of iNOS expression in normal mice in the
MAL region of the kidney in the present study is consistent with
previous results of iNOS localization primarily in the MAL region of
the normal rodent kidney.22 Mattson and Higgins have demonstrated,
using protein blotting, that greater amounts of iNOS immunoreactive
protein exist in rat renal medulla tissue homogenates.23 Nitric oxide
derived from the renal medulla has a known role in the control of
vasa recta blood flow, as well as sodium and water excretion.24,25 It
has been found that inhibition of NO synthesis predisposes both ani-
mals and humans with pre-existing renal damage to severe necrosis
of the MAL.24,25 The mechanism of hypertension after iNOS inhibition
with aminoguanidine in rats is thought to be related to decreased renal
sodium and water excretion, which leads to extracellular volume
expansion.10
The downregulation of iNOS expression in the MAL region in
hypertensive mice is consistent with the role that MAL may play in
Fig. 1 Inducible nitric oxide synthase expression in the kidney in hyperten-
sion. There is moderate expression in the distal convoluted tubules and
cortical collecting ducts (long arrows). Note the mild expression in the
proximal convoluted tubules (short arrows). Immunohistochemical stain
(original magnification ×10).
Fig. 2 Inducible nitric oxide synthase expression in the lung in hyperten-
sion. Strong expression is seen in the bronchial and vascular smooth muscle
cells (long arrows). Immunohistochemical stain (original magnification ×10).
Fig. 3 Inducible nitric oxide synthase expression in the heart in hyperten-
sion. Strong expression in cardiac myocytes is observed. Immunohistochemical
stain (original magnification ×10).
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sodium haemostasis and hypertension.26 In addition, It has been
suggested that renal medullary oxidative stress may affect blood
pressure and sodium balance via changes in NO, which inhibits
sodium chloride reabsorption by the MAL and collecting duct.26
Hypertension may also result directly from pathological alterations
to transporters, channels or enzymes that affect medullary NO.26 It
has been suggested that the mechanism of some antihypertensive
drugs, such as captopril, may involve modulation of NO activity in
specific microanatomical regions of the kidney.27 For example, NOS
activity of the renal cortex was significantly increased in spontane-
ously hypertensive rats after treatment with the antihypertensive
drug captopril.27
The results of the present study regarding iNOS expression in
other renal microanatomical locations are consistent with those of
studies, which demonstrated that iNOS is an abundant isoform of
NOS in the normal rodent kidney.21,28 Marked iNOS mRNA expression
has been demonstrated in the S3 segment of the proximal tubules, the
cortical and medullary thick ascending limbs and the cortical and inner
medullary collecting ducts, whereas minimal to mild iNOS expres-
sion was present in the thin limbs of Henle and medullary IC.21,28
Although it is well established that NO exhibits vasomodulatory
effects and inhibits the development of contractile force in the car-
diovascular system,29 the exact role that iNOS and its cardiac expression
plays in cardiac pathophysiology is poorly understood. It has been
reported that iNOS–/– mice have a HR similar to that of wild-type
mice, as well as normal blood pressure,31 and variable and conflicting
results exist in the literature regarding cardiac iNOS expression. For
example, one study reported that overexpression of iNOS in the heart
in mice has no effects on cardiac physiology and that the heart can
tolerate high levels of iNOS activity without detrimental functional
consequences.31 In contrast, another study reported an increase in
ventricular size and abnormal conduction in a transgenic mouse model
overexpressing iNOS in cardiac myocytes.32 In both the normal and
hypertensive mice in the present study, there was a high expression
of iNOS in cardiac myocytes. Marked iNOS expression has been
demonstrated in cardiac myocytes from normal aged (16 months),
but not young (6 months), mice. This may suggest that iNOS con-
tributes to age-related ventricular dysfunction. A study by Yang et al.
provided evidence for iNOS contribution to age-related ventricular
dysfunction.33 However, aged iNOS-knockout mice had ventricular
function similar to that in younger mice.33 In another study, iNOS
mRNA and protein levels in the left ventricle were elevated in
18-week-old Dahl salt-sensitive (DS) hypertensive rats, but not in
11-week-old DS rats.34 The mice in the present study were younger
(4–5 months old) than the mice used in the study of Yang et al.33
In the present study, moderate iNOS expression was observed in
alveolar macrophages and alveolar septa in normal mice, whereas
downregulated (minimal) expression was observed in hypertensive
mice. High iNOS expression in the normal lung is consistent with
previous studies that showed moderate to strong iNOS expression
in alveolar macrophages in normal bovine and rat lungs.35,36 There
is increasing evidence that free radicals play a role in the pathogenesis
of hypertension.37 Inducible NOS can produce considerable amounts
of free radicals that can react with NO to form peroxynitrite.38 The
downregulation of iNOS expression in alveolar macrophages and
alveolar septa in hypertensive mice in the present study may be
related to a unique innate pulmonary defence mechanism of alveolar
macrophages to counteract and inhibit the production of free radicals
during hypertension.
Nitric oxide plays an important role in various pulmonary epithelial
physiological processes.39 Some studies have suggested that pul-
monary EC are the primary source of expired NO.40,41 The role iNOS
plays in the lung depends on the cell type in which it is expressed
and the localization of that cell type within the lung. The upregulation
of iNOS expression in the pulmonary bronchial epithelium in hyper-
tensive mice in the present study suggests that iNOS may play a role
in regulating hypoxia induced during hypertension. Spontaneously
hypertensive rats not only have systemic hypertension, but also
pulmonary arterial hypertension,43 and chronic hypoxia-induced
pulmonary hypertension is accentuated in this model.43 In the present
study, both bronchial SMC and pulmonary VSMC showed upregu-
lation of iNOS expression during hypertension compared with controls.
This could be related to AngII activity in the transgenic mice used
in the present study. Angiotensin II is a potent vasoconstrictor of
vascular smooth muscle and has been found to potentiate bronchoc-
onstriction of rabbit airway smooth muscle.44
Nitric oxide has been identified as an endothelium-derived relaxing
factor in airway smooth muscle and vascular cells.45 In addition, NO
contributes to oxidative stress. Increased production of free radicals
and oxidative stress has been shown to impair endothelium-dependent
vasodilatation in hypertension and result in endothelial dysfunction,
which usually improves after administration of anti-oxidants.46,47 In
the present study, there was a significant downregulation of iNOS
expression in pulmonary vascular EC in control mice, whereas iNOS
expression in pulmonary vascular EC from hypertensive mice was
upregulated. These results suggest that EC dysfunction that occurs
in hypertension alters iNOS production by vascular EC. It has been
found that iNOS impairs NO-dependent vasorelaxation.45 The dif-
ferential responses between airway smooth muscle and vascular
cells may be explained by the different levels of NO, different sites
of NO production, different actions of NO and different sources of
NO.45
In conclusion, iNOS regulation in hypertension is complex and
depends on the cell type in which it is expressed and the localization
of the cell type in the cardiorenal and pulmonary systems. Experi-
ments using iNOS-specific inhibitors are needed to further characterize
the contribution of this NOS isoform in hypertension in the cardiorenal
and pulmonary systems.
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